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Summary
Background An inverse relation between Helicobacter pylori infection and allergic disease
has been reported by a range of independent epidemiological studies, but evidence from
longitudinal studies is scarce.
Objective We have investigated the effects of H. pylori infection on the incidence and
prevalence of allergic diseases and sensitization in a low-income birth cohort.
Methods In 2005/2006, a population-based birth cohort was established in Butajira, Ethi-
opia, and the 1006 singleton babies born were followed up at ages 1, 3, and 5. Symptoms
of allergic disease were collected using the ISAAC questionnaire, allergen skin tests per-
formed, and stool samples analysed for H. pylori antigen and geohelminths. Multiple
logistic regression was used to determine the independent effects of H. pylori measured at
age 3 on the incidence of each outcome between ages 3 and 5 years (in those without the
outcome at age 3), controlling for potential confounders, and to additionally assess cross-
sectional associations.
Results A total of 863 children were followed up to age 5. H. pylori infection was found
in 25% of the children at both ages 3 and 5, in 21% at age 5 but not 3, and in 17% at
age 3 but not at age 5. H. pylori infection at age 3 was significantly associated with a
decreased risk of incident eczema between ages 3 and 5 (adjusted OR, 95% CI, 0.31;
0.10–0.94, P = 0.02). Cross-sectionally at age 5, H. pylori infection was inversely
associated with skin sensitization (adjusted OR, 95% CI, 0.26; 0.07–0.92, P = 0.02).
Conclusion and clinical relevance These findings provide further evidence to suggest that
early-life exposure to H. pylori may play a protective role in the development of allergy.
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Introduction
There is wide geographical variation in the prevalence
of asthma and allergic conditions world-wide, with sub-
stantial differences seen between low- and high-income
countries, and between urban and rural communities
[1–3]. Our group’s previous work in Ethiopia has found
a threefold higher prevalence of asthma symptoms in
urban compared with rural areas [2]. This observation
raises the hypothesis that environmental factors,
possibly interacting with genetic determinants, or other
factors related to urban–rural socio-economic disparity,
are likely to be important [3, 4].
As part of the hygiene hypothesis, much recent
interest has focused on the protective role of Helicob-
acter pylori infection in the aetiology of asthma and
allergic disease. This has gained support from a range
of epidemiological [5–9], epigenetic [10], and animal
model studies [11]. Reduced risks of atopy and asthma
have been seen in many human studies [5–10, 12, 13],
both in children [5, 6, 12, 14] and adults [7, 13].
H. pylori is a bacterium which colonizes the gastric
mucosa of approximately half the world’s population
and is the main cause of peptic ulcer disease and
gastric adenocarcinoma [15]. The infection is usually
established during early childhood, persists life long,
and remains asymptomatic in over 85% of cases. It
has been suggested that humans have co-evolved with
H. pylori and are physiologically adapted to be
colonized by these bacteria [16]. The prevalence of
H. pylori infection in developed countries has been
declining sharply for several years, however [17]. The
proportion of young children becoming infected is
now extremely low, most probably due to antibiotic
use [18]. Puzzlingly, there has also been a selective
decline in the more virulent CagA+ strains of H. pylori
[19]. In opposition to this, between 1973 and 1994,
Kosunen et al. [20] found that markers of allergy
increased by more than threefold, with the increase
mainly occurring in H. pylori-negative subjects [20].
These findings are therefore consistent with a secular
trend: as H. pylori infection has declined [19, 20],
asthma prevalence has risen [3].
Whilst the role of H. pylori in asthma and allergic
disease aetiology is intriguing, most of the studies to
date are of cross-sectional or case–control design and
based in adult high-income country populations, with
very few conducted in children. This is important as
H. pylori is usually acquired in childhood, and its stim-
ulation of the immune system as it develops could be
protective [21]. Alternative explanations for the inverse
trends, including reverse causation and bias due to
antibiotic eradication therapy affecting H. pylori acqui-
sition, are difficult to exclude. Therefore, we have used
data from our Ethiopian birth cohort followed to age 5,
to longitudinally determine the effects of H. pylori
infections on the incidence of allergic diseases and
sensitization, and additionally explore cross-sectional
associations at age 5. Cross-sectional associations
between H. pylori and geohelminth infections and
allergic outcomes at age 3 have been reported
previously [14]; prevalence of geohelminth infection
in this cohort was too low to explore this exposure
further.
Methods
The study setting and the birth cohort
In 2005, a birth cohort was established in Butajira,
Ethiopia, details of which have been described previ-
ously [22]. In brief, all pregnant women living in the
study area were recruited in their third trimester
(N = 1065) and subsequently gave birth to 1006 single-
ton live babies who were followed at regular intervals
to age 5 (Fig. 1).
Data collection and measurements
At ages 1-, 3-, and 5-year follow-ups, female data col-
lectors who knew the study setting visited the mothers
at home, administered an interview led questionnaire,
usually within 2 weeks of the child’s birthday. The
questionnaire included questions on wheeze, eczema,
rhinitis, and asthma based on the International Study of
Asthma and Allergies in Children (ISAAC) core allergy
and environmental questionnaire as in our previous
studies at age 1- [23, 24] and 3-year follow-up [14, 25].
For wheeze: ‘Has your child ever had (or in the past
12 months) had wheezing or whistling in their chest?’
Eczema: ‘Has your child ever had (or in the past
12 months) had an itchy skin rash which has affected
the skin creases (e.g. front of the elbow, behind the
knees, the front of the ankles, around the neck, or
around the eyes?’) Rhinitis: ‘Has your child ever had (or
in the past 12 months) had problems with sneezing
or running nose (when not affected by cold or flu), or
1065 women recruited
1006 singleton babies born 
alive
932 singleton babies available at one 
year follow-up
878 singleton babies available at 
three year follow-up
(H. pylori data collected in 616) 
863 singleton babies available at 
five year follow-up (600 with
data on H. pylori at age 3) 
2 child deaths
11 out migrated
1 refusal
1 unknown
855 provided skin test 
data of whom (854 with 
H. pylori data at age 5 
and 597 at age 3 and 5)
852 reported outcome 
data (847 with H. pylori 
data at age 5 and 593 
at age 3 and 5)
Fig. 1. Cohort of children from birth until age 5.
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problems with itchy watery eyes?’ Information was also
collected on a range of potential confounders, including
familial factors (maternal and paternal history of
asthma and allergy); childhood factors (immunization,
breastfeeding status, birth order, number of siblings,
child’s use of antibiotic); household characteristics (roof
type, household size and child’s sleeping place); and
environmental factors (indoor pollution including
indoor cooking, indoor kerosene use, and insecticide
use).
At ages 3 and 5, skin sensitization to D. pteronyssinus
and cockroach allergen (Blattella germenica; Biodiagnos-
tics, Upton-upon-Severn, UK), previously found to be
common in an Ethiopian population [26], was measured
on each child using skin-prick lancets. We demonstrated
a reasonably good inter-rater agreement amongst the
fieldworkers who did the test (j = 0.67, P < 0.01 for
cockroach allergen, and, j = 0.63, P < 0.01 for D. pter-
onyssinus allergen).
Also, a rapid test (Medimar immunocard) was used to
determine H. pylori antigen in stool samples (Biohit,
Unit 1 Barton Hill Way, UK) collected at age 3 from a
randomly chosen subsample of children (N = 616) and
at age 5 from all available children (N = 863). Analysis
of geohelminth infections was also carried out on the
stool samples.
Data management and statistical analysis
Data were double-entered into EpiData, version 3,
cleaned, coded, and merged using Stata 11 (Statacorp,
College Station, TX, USA). For analysis of incident
wheeze between ages 3 and 5, those children without
reported wheeze at ages 1 and 3 (negative response to
wheeze in the past 12 months, at years 1 and 3, and
wheeze ever at year 3) were selected for analysis and
incident wheeze defined as a positive response at the
year 5 follow-up. Eczema and rhinitis were analysed in
a similar manner. Asthma was very rarely reported in
this birth cohort (1%), and therefore not analysed fur-
ther. For sensitization, those children who were not
sensitized at age 3 (sensitization defined as an average
of two perpendicular weal diameters, one of which was
the maximum measurable diameter, of at least 3 mm
greater than the saline control response) were selected
for analysis, and new-onset sensitization defined as a
positive result at age 5. As the prevalence of cockroach
allergen at age 5 was low, a separate analysis of each
allergen was not possible; instead, a combined variable
‘any sensitization’ was created to refer to sensitization
to either D. pteronyssinus or cockroach allergen. For all
longitudinal analyses, the exposure variable used was
H. pylori infection at age 3.
For cross-sectional analysis, the outcomes were
wheeze, eczema, and rhinitis in the past 12 months as
reported at age 5 and sensitization to either D. pter-
onyssinus or cockroach allergen. The effects of
H. pylori infection, for all available children at year 5,
were analysed by first creating a new exposure variable
with categories representing different combinations of
infection status at ages 3 and 5: ‘never infected’ (never
infected at both time-points), ‘infected at year 3 but not
at year 5’, ‘infected at year 5 but not at year 3’, or ‘per-
sistently infected’ (infected at both time-points). For the
sensitization outcome at year five, however, numbers of
children in some exposure categories were low and it
was therefore necessary to merge the exposed catego-
ries to create a single category ‘exposed at any age up
to year 5’. Moreover, an additional separate analysis of
the effects of H. pylori infection using only data col-
lected at age five was conducted (infected vs. not
infected at age 5), as these analyses are on larger sam-
ple sizes than the longitudinal analyses, and benefit
from greater statistical power.
Univariate analyses with crude odds ratios (OR) and
95% confidence intervals (CI) for each outcome in rela-
tion to H. pylori infection were conducted. Multivariate
logistic regression was then used to determine the inde-
pendent effects of H. pylori on each incident and
prevalent outcome, controlling for the a priori con-
founders, and adjusted ORs, and 95% CIs obtained. The
a priori confounders were place of residence (urban/
rural), child’s gender, and maternal education (as a
marker of socioeconomic status). The impact of further
controlling for any other potential confounders includ-
ing breastfeeding, antibiotic use, and geohelminth
infection was also explored (Tables S1 and S2). These
covariates were retained in the model if they have
altered the odds ratios for the main exposure of interest
by more than 10%. The significance of the association
between exposure and outcome in the model was
assessed using a likelihood ratio test for the association
(LRT).
Ethics
Ethical approval was granted by the Institutional
Review Board (IRB) of Addis Ababa University, the
National Ethical Review Committee of the Ethiopian
Science and Technology Ministry, and the University of
Nottingham, United Kingdom. Written informed consent
was obtained from all participants at each study visit.
Results
Follow-up of cohort at age 5
Year 1 and 3 follow-ups of the birth cohort have been
previously described [14, 23]. In brief, 863 singleton
children were successfully followed up at year 5 (86%
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of the original cohort at birth, and 97% of those avail-
able at year 3 follow-up), of whom 847 had symptom
and H. pylori data at this time-point, and 854 had sen-
sitization and H. pylori data (Fig. 1). Amongst the
wheeze-free cohort at age 3, the incidence of new-onset
wheeze (wheeze reported at age 5) was 5.9% (40/676);
similarly, the incidence of eczema was 5.8% (39/700),
rhinitis 3.9% (31/798), and sensitization (to either
D. pteronyssinus or cockroach allergen) was 2.0% (15/
766; Table 1). Sensitization early in life increased the
risk of later onset eczema and rhinitis (Table 2). Effects
of potential confounders on the outcomes and associa-
tions with H. pylori at age 5 are found in the online
supplement (Tables S1–S3).
Helicobacter pylori infection at ages 3 and 5
Helicobacter pylori infection was common with 41% of
children infected at age three (described previously
[14]) and 44% (377/857) at age five. A pattern of unsta-
ble H. pylori infection was found such that 17% (102/
600) of children were infected at age three but not five,
21% (121/600) at age five but not 3 years, and 25%
(147/600) at both ages. Moreover, the prevalence of
H. pylori infection at age 5 did not significantly differ
by urban or rural area of residence such that 50% (52/
104) of urban children and 43% (325/753) of rural chil-
dren have current infection.
Effects of H. pylori infection on incidence of allergic
outcomes between ages 3 and 5
In multivariate analysis adjusted for a priori confound-
ers, H. pylori infection at age 3 was positively,
although not significantly related to incident wheeze
(adjusted OR, 95% CI, 1.56; 0.69, 3.51, P = 0.28;
Table 3). Infection, however, was significantly inversely
associated with incident eczema, after control for a pri-
ori confounders and further control for breastfeeding
history in the first year of life (adjusted OR, 95% CI,
0.31; 0.10, 0.94, P = 0.02; Table 4). Adjustment for
other potential confounders made little change to the
odds ratio. No significant effects of H. pylori were seen
on incident rhinitis or sensitization (Table 5 and 6).
Effects of H. pylori infection on prevalence of allergic
outcomes at age 5
The analysis of the four-level H. pylori infection vari-
able representing timing of infection revealed the low-
est prevalence of the outcomes amongst children
infected at age 3 but not at 5, and consistently reduced
ORs in infected children for eczema and sensitization,
but overall associations did not reach statistical signifi-
cance (Tables 3–6). The exposure variable representing
current H. pylori infection (at age 5) was inversely
associated with all outcomes at age 5 except wheeze
and reached statistical significance for sensitization
(adjusted OR, 95% CI, 0.26; 0.07, 0.92, P = 0.02;
Table 6). Further adjustment for potential confounders,
including childhood and household characteristics, did
not materially alter these cross-sectional associations.
Discussion
This study provides important insights into the role of
H. pylori in relation to allergic disease and sensitiza-
tion. As with our study at year 3 follow-up [14], this
Table 1. Incidence of the outcomes by area of residence
Incident outcome†
Overall
n (%)
Urban
Yes n (%)
Rural
Yes n (%)
Crude OR
(95% CI) P-value
Wheeze (N = 676) 40 (5.9) 2 (2.6) 38 (6.4) 0.39 (0.09, 1.64) 0.18
Eczema (N = 700) 39 (5.8) 2 (2.4) 37 (6.0) 0.38 (0.09, 1.62) 0.17
Rhinitis (N = 798) 31 (3.9) 2 (2.0) 29 (4.2) 0.48 (0.11, 2.03) 0.30
Any sensitization* (N = 766) 15 (2.0) 1 (1.1) 14 (2.1) 0.54 (0.07, 4.15) 0.55
*Sensitization to either D. pteronyssinus or cockroach allergen.
†Incidence computed in each cohort of children without the outcome at age 3, and incident outcome defined as having the outcome at age 5.
Table 2. OR for incident wheeze, eczema, and rhinitis in relation to skin sensitization at the age of three
New-onset symptoms
at age 5
Any sensitization at year 3*
Over all
N (%)
Yes
n (%)
No
n (%)
Crude OR
(95% CI) P-value
Wheeze (N = 663) 40 (6.0) 5 (8.2) 35 (5.8) 1.45 (0.54, 3.84) 0.46
Eczema (N = 688) 39 (5.6) 7 (11.5) 32 (4.9) 2.49 (1.04, 5.95) 0.03
Rhinitis (N = 785) 31 (4.0) 6 (8.5) 25 (3.5) 2.54 (1.00, 6.45) 0.04
*Sensitization to either D. pteronyssinus or cockroach allergen.
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study demonstrates evidence of a protective effect of
H. pylori on eczema and sensitization in young children
in a low-income birth cohort in which confounding by
social advantage or antibiotic therapy is unlikely to
play a role. In the longitudinal analysis, infection with
H. pylori was associated with a 69% decreased risk of
incident eczema, and in the cross-sectional analysis,
current exposure to H. pylori infection at year 5 was
associated with a 74% decreased risk of sensitization.
However, no significant associations, cross-sectionally
or longitudinally, were seen for wheeze and rhinitis,
and the directions of the ORs were inconsistent.
The use of a low-income setting prospective birth
cohort in assessing the hypothesis that H. pylori infec-
tion protects against wheeze and allergic diseases has
several strengths. The prospective design provides infor-
mation on temporal relations between the exposure and
outcome, hence reverse causation is unlikely to have
played a role in this study. Furthermore, the birth
cohort design meant it was possible to explore the tim-
ing of H. pylori exposure, and association with allergic
diseases, which has barely been explored in most previ-
ous studies. The study also demonstrated very good
retention of the surviving mother–child dyads up to the
Table 4. Longitudinal and cross-sectional analyses of eczema in relation to exposure to Helicobacter pylori infection
Longitudinal analysis of incident
eczema between ages 3 and 5 (N = 498)*
Overall
N (%)
Outcome
Yes
n (%)
Outcome
No
n (%)
Crude OR
(95% CI)
Adjusted OR†
(95% CI) P-value
H. pylori exposure at year 3
No 293 (58.8) 18 (6.1) 275 (93.9) 1 1
0.02Yes 205 (41.2) 5 (2.4) 200 (97.6) 0.38 (0.14, 1.05) 0.31 (0.10, 0.94)
Cross-sectional analysis of eczema at age 5
H. pylori exposure at age 5 (N = 847)
No 477 (56.3) 24 (5.0) 453 (95.0) 1 1
0.19Yes 370 (43.7) 12 (3.2) 358 (96.8) 0.63 (0.31, 1.28) 0.63 (0.31, 1.28)
H. pylori exposure at ages 3 and 5 (N = 593)‡
Never infected 222 (37.4) 15 (6.8) 207 (93.2) 1 1 0.16
Infected at age 3 but not at age 5 101 (17.0) 2 (2.0) 99 (98.0) 0.28 (0.06, 1.26) 0.29 (0.06, 1.28)
Infected at age 5 but not at age 3 126 (21.3) 5 (4.0) 121 (96.0) 0.57 (0.20, 1.61) 0.54 (0.19, 1.54)
Persistent exposure 144 (24.3) 4 (2.8) 140 (97.2) 0.39 (0.13, 1.22) 0.40 (0.13, 1.24)
*Reduced numbers as longitudinal analysis performed only on those reporting never eczema at age 3.
†ORs adjusted for child’s gender, area of residence, and maternal education and further adjusted controlled for history of breastfeeding in the first
year of life.
‡Reduced numbers as H. pylori measured on subsample only at age 3.
Table 3. Longitudinal and cross-sectional analyses of wheeze in relation to exposure to Helicobacter pylori infection
Longitudinal analysis of incident
wheeze between ages 3 and
5 (N = 474)*
Overall
N (%)
Outcome
Yes
n (%)
Outcome
No
n (%)
Crude OR
(95% CI)
Adjusted OR†
(95% CI) P-value
H. pylori exposure at year 3
No 273 (57.6) 12 (4.4) 261 (95.6) 1 1
0.28Yes 201 (42.4) 13 (6.5) 188 (93.5) 1.50 (0.67, 3.37) 1.56 (0.69, 3.51)
Cross-sectional analysis of wheeze at age 5
H. pylori exposure at age 5 (N = 847)
No 477 (56.3) 18 (3.8) 459 (96.2) 1 1
0.35Yes 370 (43.7) 19 (5.1) 351 (94.9) 1.38 (0.71, 2.67) 1.37 (0.71, 2.65)
H. pylori exposure at ages 3 and 5 (N = 593)‡
Never infected 222 (37.4) 10 (4.5) 212 (95.5) 1 1 0.52
Infected at age 3 but not at age 5 101 (17.0) 3 (3.0) 98 (97.0) 0.65 (0.17, 2.42) 0.62 (0.16, 2.30)
Infected at age 5 but not at age 3 126 (21.3) 5 (4.0) 121 (96.0) 0.88 (0.29, 2.63) 0.89 (0.30, 2.68)
Persistent exposure 144 (24.3) 10 (6.9) 134 (93.1) 1.58 (0.64, 3.91) 1.52 (0.61, 3.77)
*Reduced numbers as longitudinal analysis performed only on those reporting never wheeze at age 3.
†ORs adjusted for child’s gender, area of residence, and maternal education.
‡Reduced numbers as H. pylori measured on subsample only at age 3.
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age of 5 years, with less than 6% lost to follow-up
between birth and five. H. pylori was measured objec-
tively using stool antigen testing, a reliable epidemio-
logical method to determine current infection status in
young children with sensitivity of 90% and specificity
of 93% [27], although we were unable to specifically
measure the strains of H. pylori. Other studies have
shown protective associations to be particularly strong
for the more virulent CagA+ H. pylori strains [28]. The
prevalence of H. pylori infection was higher than that
observed in more economically developed countries
[29], with a small increase in incident H. pylori
infections with ageing as expected.
Our findings, however, must be interpreted in the
light of several limitations. Whilst the sensitization
outcome was measured objectively, measures of wheeze,
eczema and rhinitis were based on maternal question-
naire reporting, and hence are susceptible to reporting
or recall bias. This is, however, based on the widely
validated ISAAC symptoms questionnaire [30], which
has been successfully used by our group in under five
children [31, 32], and in older age groups [2, 26]. More-
over, incidence and prevalence of the study outcomes
appeared to be positively related to sensitization; albeit
weakly with wheeze, and with maternal and paternal
allergy, suggesting that some of these are markers of
allergy. Even though validated symptom based-ques-
tionnaires were used, as these are most practical for a
population-based epidemiological study [33], the lack
of objective measures of asthma is a limitation. The
implications of poor recall on the findings are that
some incident cases may have been missed if symptoms
Table 6. Longitudinal and cross-sectional analyses of sensitization in relation to exposure to Helicobacter pylori infection
Longitudinal analysis of incident sensitization
between ages 3 and 5 (N = 552)*
Overall
N (%)
Outcome
Yes
n (%)
Outcome
No
n (%)
Crude OR
(95% CI)
Adjusted OR†
(95% CI) P-value
H. pylori exposure at year 3
No 318 (57.6) 7 (2.2) 311 (97.8) 1 1
0.72Yes 234 (42.4) 6 (2.6) 228 (97.4) 1.17 (0.39, 3.53) 1.23 (0.40, 3.37)
Cross-sectional analysis of sensitization at age 5
H. pylori exposure at age 5 (N = 854)
No 479 (56.1) 14 (2.9) 465 (97.1) 1 1
0.02Yes 375 (43.9) 3 (0.8) 372 (99.2) 0.27 (0.08, 0.94) 0.26 (0.07, 0.92)
H. pylori exposure at ages 3 and 5 (N = 597)‡
Never infected 224 (37.5) 7 (3.1) 217 (96.9) 1 1 0.36
Infected at any age up to year 5 373 (62.5) 7 (1.9) 366 (98.1) 0.59 (0.21, 1.71) 0.61 (0.21, 1.76)
*Reduced numbers as longitudinal analysis performed only on those reporting never sensitization at age 3.
†ORs adjusted for child’s gender, area of residence, and maternal education.
‡Reduced numbers as H. pylori measured on subsample only at age 3.
Table 5. Longitudinal and cross-sectional analyses of rhinitis in relation to exposure to Helicobacter pylori infection
Longitudinal analysis of incident rhinitis
between ages 3 and 5 (N = 559)*
Overall
N (%)
Outcome
Yes
n (%)
Outcome
No
n (%)
Crude OR
(95% CI) Adjusted OR† (95% CI) P-value
H. pylori exposure at year 3
No 334 (59.8) 13 (3.9) 321 (96.1) 1 1
0.88Yes 225 (40.3) 10 (4.4) 215 (95.6) 1.15 (0.49, 2.67) 1.07 (0.45, 2.57)
Cross-sectional analysis of rhinitis at age 5
H. pylori exposure at age 5 (N = 847)
No 477 (56.3) 18 (3.8) 459 (96.2) 1 1
0.86Yes 370 (43.7) 13 (3.5) 357 (96.5) 0.93 (0.45, 1.92) 0.94 (0.45, 1.94)
H. pylori exposure at ages 3 and 5 (N = 593) ‡
Never infected 222 (37.4) 9 (4.1) 213 (96.0) 1 1 0.83
Infected at age 3 but not at age 5 101 (17.0) 3 (3.0) 48 (97.0) 0.72 (0.19, 2.74) 0.73 (0.19, 2.76)
Infected at age 5 but not at age 3 126 (21.3) 3 (2.4) 123 (97.6) 0.56 (0.15, 2.18) 0.60 (0.16, 2.26)
Persistent exposure 144 (24.3) 6 (4.2) 138 (95.8) 1.03 (0.36, 2.96) 1.05 (0.36, 3.03)
*Reduced numbers as longitudinal analysis performed only on those reporting never rhinitis at age 3.
†ORs adjusted for child’s gender, area of residence, and maternal education.
‡Reduced numbers as H. pylori measured on subsample only at age 3.
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only occurred early in the 1- to 3-year follow-up period
and did not persist up to the age of 5, although such
non-persistent cases are likely to be those with mild
disease. Multiple testing might be an issue; however,
the consistency of both cross-sectional and longitudinal
analyses at a range of time-points makes the possibility
that these are chance findings unlikely. A further limi-
tation of the study is that some analyses, particularly
longitudinal analyses, suffered from low numbers in
some groups which resulted in some wide confidence
intervals and hence imprecision of effect estimates. We
have only tested a subsample of children at age 3
(n = 616 children of 878 available children at age 3)
and a complete sample of children at age 5. The impli-
cation is that this might have introduced a degree of
bias in relation to the outcomes, although this bias is
likely to be non-differential. Moreover, we have no data
on H. pylori status of these children younger than
3 years and hence were unable to assess the prevalence
of infection in the first year of life as well as associa-
tions with our outcomes. Finally, the presence of
H. pylori infection may simply be a marker for other
microbes or poor hygiene practices that protect against
atopic disease [34, 35] and hence the associations that
we report are not a direct biological effect of the pres-
ent of the H. pylori bacterium itself.
Most studies investigating the link between H. pylori
infection and asthma and allergic disease to date have
been cross-sectional or case–control in design [9]. Stud-
ies in young children, particularly those from low-
income countries, are remarkably scarce, with only few
studies reporting links in children [5, 6]. In this study,
we have found a significant inverse association between
early-life exposure to H. pylori infection and the risk
of incident eczema between ages 3 and 5 (adjusted
OR = 0.31). This finding is in agreement with our previ-
ous study in the same cohort [14] and other available
cross-sectional studies in children [5, 6]. Amongst the
US-based studies in children (age 3–19 years), the
National Health and Nutrition Examination Survey
(NHANES IV) reported significant inverse association
between H. pylori seropositivity and eczema (adjusted
OR = 0.73) [5]. Our findings are also consistent with
data reported by Herbarth et al. [6] from Germany who
found a 63% reduction in doctor-diagnosed eczema in
children (mean age 6.3 years) infected to H. pylori. The
difference in size of the ORs may be due to variation in
age, outcome ascertainment, level of infection (e.g. the
prevalence of H. pylori in these studies was < 10%
[5, 6] compared with > 40% in ours), and differences in
measurement of infection status (serology vs. rapid stool
antigen test used in the current study).
This study also provides some evidence, although
cross-sectional, for an inverse association of H. pylori
with sensitization at age 5 (adjusted OR = 0.26). Most
of the available observational studies in children did
not specifically explore the effects of H. pylori on sen-
sitization [5, 6]. In a study comparing Finnish and Rus-
sian children, the prevalence of atopic sensitization was
higher in Finland than Russia, and it appeared that this
was due to an inverse association with H. pylori infec-
tion [12]. Even though it is difficult to draw direct
inference from studies in adults, our findings fit with
cross-sectional studies in these age groups [7, 10, 13].
The NHANES III survey in the United States demon-
strated an inverse association with sensitization to pol-
len and moulds, with a larger association seen in
younger subjects (median age < 43 years) and those
infected with CagA+ strains (OR = 0.69) [7]. However,
the same group of investigators in another study
reported no association between H. pylori infection and
serum IgE [13].
One explanation for these findings might be reverse
causation, through use of antibiotics, in that use for
asthma or allergy may in turn affect H. pylori infection.
Even though this remains a possibility, in the current
study, in children from a low-income cohort with limited
access to standard antibiotics and no H. pylori eradica-
tion programme, this was less likely to be a source of
bias. Although reverse causation may be an issue in the
cross-sectional analyses, replication of findings in the
longitudinal analyses excludes this possibility. H. pylori
status might also be a proxy indicator of other infections
or socio-economic conditions [6, 36]. To explore such a
possibility, the findings were controlled for markers of
socio-economic status, which may have confounded the
previous study [8], and adjusted for other infections
including geohelminth infections, and commensal bacte-
ria, but no evidence was found to support this argument.
The study did not detect an association of H. pylori
with wheeze or rhinitis in this cohort of young children
on either cross-sectional or longitudinal analyses. One
previous study in children, the NHANES IV study,
showed reduction in ever having had asthma (OR = 0.69)
or allergic rhinitis (OR = 0.60) amongst H. pylori
infected subjects [5]. Another US-based study in adults
also reported inverse associations, and it appeared that
the associations were stronger in younger adults (median
age < 43 years), for asthma and rhinitis cases with onset
during childhood (≤ 15 years), and in those infected by
CagA+ strains [7]. The lack of associations with reported
wheeze and rhinitis in this study may be due to mecha-
nisms other than those related to wheeze or asthma
physiopathology, or to outcomes partly unrelated to
allergic phenotype [37, 38]. Another explanation may be
that these observations relate mainly to H. pylori CagA+
strains, as these have been reported to have strong
effects on asthma [7, 9]. We have no data on CagA
serology; however, a previous study in dyspeptic
Ethiopian patients detected CagA genes in 79% of the
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study subjects [39], suggesting this may be the dominant
strain in the population, and perhaps also explaining the
strong protective associations seen in the study.
Plausible mechanisms in support of these observations
also exist. Studies have shown that the H. pylori-induced
inflammatory response is associated with Th1-mediated
cellular responses [28, 40], with higher expression of
interferon-c (IFN-c) [40], IL-10, and IL-12 [41]. Particu-
larly strong effects were seen in those possessing the
pathogenic CagA+ strains [28, 41]. The protective
effects of H. pylori against allergy are also mediated by
secretion of regulatory T cells (Tregs) [42] that suppress
immunity and inflammation via bystander effects of
IL-10 [42].
In conclusion, our data are consistent with the hypoth-
esis that H. pylori has a protective role against allergy,
particularly eczema and sensitization, although further
study is needed to establish causality. Investigations of
the immunological mechanisms involved may enhance
our understanding of the interactions between the gut
microbiome and allergic disease, possibly allowing thera-
peutic manipulation of these pathways in the future in
the primary prevention or treatment of these conditions.
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